Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 311: Methemoglobinemia can be treated by which of the following agents?

A. Methylene blue (Correct Answer)
B. Vitamin K
C. Vitamin A
D. All of the above

Explanation: **Explanation:** **1. Why Methylene Blue is the Correct Answer:** Methemoglobinemia occurs when the iron in hemoglobin is oxidized from the ferrous state ($Fe^{2+}$) to the **ferric state ($Fe^{3+}$)**. Ferric iron cannot bind oxygen, and it increases the oxygen affinity of remaining heme groups (shifting the dissociation curve to the left), leading to tissue hypoxia and characteristic "chocolate-colored blood." **Methylene blue** acts as a cofactor for the enzyme **NADPH-methemoglobin reductase**. It is reduced to leukomethylene blue, which then donates an electron to the $Fe^{3+}$ (ferric) iron, converting it back to the functional $Fe^{2+}$ (ferrous) state [1]. This restores the oxygen-carrying capacity of the blood. **2. Why the Other Options are Incorrect:** * **Vitamin K:** This is the antidote for **Warfarin overdose** and is essential for the synthesis of clotting factors II, VII, IX, and X [2]. It has no role in the redox state of hemoglobin. * **Vitamin A:** This is a fat-soluble vitamin essential for vision and epithelial integrity. Deficiency leads to night blindness and xerophthalmia, but it does not treat blood dyscrasias. **3. Clinical Pearls for NEET-PG:** * **Drug-induced causes:** Common culprits include **Nitrites, Benzocaine, Dapsone, and Sulfonamides.** * **Clinical Sign:** Patients present with cyanosis that does not improve with supplemental oxygen and a "saturation gap" (difference between $SpO_2$ and $PaO_2$). * **Alternative Treatment:** High-dose **Vitamin C (Ascorbic acid)** can be used if Methylene blue is unavailable or contraindicated. * **Contraindication:** Methylene blue is contraindicated in patients with **G6PD deficiency**, as it can precipitate severe hemolysis (due to insufficient NADPH).

Question 312: HLA-B* 1502 is a genetic marker for which of the following conditions?

A. Systemic lupus erythematosus
B. Polyarteritis nodosa
C. Stevens-Johnson syndrome (Correct Answer)
D. Seronegative spondyloarthritis syndrome

Explanation: **Explanation:** **HLA-B*1502** is a strong genetic predictor for the development of **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)**, specifically when triggered by the anticonvulsant drug **Carbamazepine**. This association is most prevalent in populations of Han Chinese, Southeast Asian, and Indian descent. The presence of this allele leads to an altered immune response where cytotoxic T-cells are inappropriately activated against keratinocytes, causing widespread epidermal detachment. **Analysis of Options:** * **Option C (Correct):** HLA-B*1502 is the specific marker for Carbamazepine-induced SJS/TEN. Screening for this allele is now mandatory in high-risk populations before initiating therapy. * **Option A (Incorrect):** Systemic Lupus Erythematosus (SLE) is more commonly associated with **HLA-DR2** and **HLA-DR3**. Drug-induced lupus (e.g., by Hydralazine or Procainamide) is linked to the **Slow Acetylator** phenotype (NAT2 deficiency). * **Option B (Incorrect):** Polyarteritis Nodosa (PAN) is a systemic necrotizing vasculitis strongly associated with **Hepatitis B virus (HBV)** infection rather than a specific HLA-B marker. * **Option D (Incorrect):** Seronegative spondyloarthritis (including Ankylosing Spondylitis) is classically associated with **HLA-B27**. **High-Yield Clinical Pearls for NEET-PG:** * **HLA-B*5701:** Associated with hypersensitivity to **Abacavir** (Antiretroviral). * **HLA-B*5801:** Associated with SJS/TEN induced by **Allopurinol**. * **HLA-A*3101:** Another marker for Carbamazepine hypersensitivity, more common in Europeans. * **Drug of Choice for SJS/TEN:** Supportive care and IV Immunoglobulins (IVIG). Cyclosporine is also used.

Question 313: Alkalinization of urine is done in which of the following drug poisonings?

A. Amphetamine
B. Morphine
C. Phenobarbitone (Correct Answer)
D. Digoxin

Explanation: **Explanation:** The principle behind urinary pH manipulation is **Ion Trapping**. According to the Henderson-Hasselbalch equation, acidic drugs are more ionized (charged) in an alkaline medium. Since ionized drugs are lipid-insoluble, they cannot be reabsorbed across the renal tubular epithelium and are excreted in the urine. **1. Why Phenobarbitone is Correct:** Phenobarbitone is a **weakly acidic drug**. By administering intravenous Sodium Bicarbonate ($NaHCO_3$), the urine is alkalinized (pH > 7.5). This converts the drug into its ionized form within the renal tubules, "trapping" it in the urine and significantly enhancing its clearance. This method is also used for **Salicylate (Aspirin)** poisoning. **2. Analysis of Incorrect Options:** * **Amphetamine:** This is a **weakly basic drug**. To enhance its excretion, **urinary acidification** (using Ammonium Chloride) was historically used. However, this is rarely done clinically now due to the risk of metabolic acidosis and rhabdomyolysis. * **Morphine:** It is an opioid with a large volume of distribution and is primarily metabolized by the liver (glucuronidation). Urinary pH manipulation is ineffective for morphine clearance. * **Digoxin:** It has a very high volume of distribution ($V_d$) and binds extensively to cardiac tissue. Hemodialysis or urinary pH changes do not affect its clearance; management involves Digoxin-specific Fab fragments (Digibind). **Clinical Pearls for NEET-PG:** * **Alkalinization (Sodium Bicarbonate):** Used for Salicylates, Phenobarbitone, Methotrexate, and Chlorpropamide. * **Acidification (Ammonium Chloride):** Theoretically for Amphetamine, Quinine, and Phencyclidine (rarely used). * **Forced Alkaline Diuresis:** No longer routinely recommended; simple alkalinization is preferred to avoid fluid overload.

Question 314: Which of the following statements is not true about Tacrolimus?

A. It is a macrolide antibiotic
B. It is indicated for the prophylaxis of organ transplant rejection
C. Glucose intolerance is a well recognized side effect
D. It can be safely administered with any nephrotoxic drug (Correct Answer)

Explanation: **Explanation:** Tacrolimus is a potent immunosuppressant belonging to the **calcineurin inhibitor (CNI)** class. Understanding its mechanism and side effect profile is crucial for NEET-PG. **Why Option D is the Correct Answer (The "Not True" Statement):** Tacrolimus is inherently **nephrotoxic**. It causes vasoconstriction of the afferent arterioles, leading to decreased glomerular filtration rate (GFR). Therefore, it **cannot** be safely administered with other nephrotoxic drugs (such as Aminoglycosides, Amphotericin B, or NSAIDs) as this significantly increases the risk of acute kidney injury (AKI). **Analysis of Other Options:** * **Option A:** Tacrolimus is chemically a **macrolide** (derived from *Streptomyces tsukubaensis*), though it lacks antibacterial activity. It acts by binding to the **FK-binding protein (FKBP-12)** to inhibit calcineurin. * **Option B:** It is a first-line agent for the **prophylaxis of organ transplant rejection** (especially liver and kidney), being 10–100 times more potent than Cyclosporine. * **Option C:** **New-onset diabetes after transplantation (NODAT)** or glucose intolerance is a well-documented side effect. Tacrolimus is more diabetogenic than Cyclosporine. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effect Profile:** Nephrotoxicity, Neurotoxicity (tremors, seizures), Hypertension, and Hyperkalemia. * **Comparison with Cyclosporine:** Unlike Cyclosporine, Tacrolimus does **not** cause hirsutism or gingival hyperplasia. * **Monitoring:** It has a narrow therapeutic index; hence, **Therapeutic Drug Monitoring (TDM)** is mandatory. * **Topical Use:** It is used topically for **Atopic Dermatitis** (Pimecrolimus is another drug in this class).

Question 315: The immunosuppressant action of cyclosporine appears to be due to which of the following mechanisms?

A. Activation of Natural Killer (NK) cells
B. Blockade of tissue responses to inflammatory mediators
C. Inhibition of gene transcription of interleukins (Correct Answer)
D. Interference with antigen recognition

Explanation: ### Explanation **Mechanism of Action (The Correct Answer):** Cyclosporine is a **calcineurin inhibitor**. Under normal physiological conditions, when a T-cell is activated, intracellular calcium increases and binds to **calmodulin**. This complex activates calcineurin, a phosphatase that dephosphorylates **NFAT** (Nuclear Factor of Activated T-cells). Dephosphorylated NFAT enters the nucleus to promote the **transcription of interleukin genes**, primarily **IL-2**, which is essential for T-cell proliferation. Cyclosporine binds to its cytoplasmic receptor, **cyclophilin**, and this complex inhibits calcineurin. Consequently, NFAT remains phosphorylated, cannot enter the nucleus, and the transcription of IL-2 and other cytokines (IL-3, IFN-gamma) is inhibited. **Analysis of Incorrect Options:** * **Option A:** Cyclosporine actually **suppresses** cell-mediated immunity; it does not activate NK cells. * **Option B:** This describes the action of anti-inflammatory drugs like antihistamines or NSAIDs. Cyclosporine acts upstream by preventing the production of cytokines rather than blocking their peripheral tissue effects. * **Option D:** Cyclosporine does not interfere with the initial MHC-antigen recognition by the T-cell receptor; it blocks the subsequent intracellular signaling cascade. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For prophylaxis of graft-versus-host disease in organ transplantation. * **Adverse Effects (The "H" Mnemonic):** **H**ypertension, **H**irsutism, **H**yperplasia of gums (gingival hyperplasia), **H**yperlipidemia, and **H**epatotoxicity. * **Most Serious Side Effect:** **Nephrotoxicity** (dose-related and the most common reason for dose limitation). * **Metabolism:** Metabolized by **CYP3A4**; beware of interactions with grapefruit juice (inhibitor) or Rifampicin (inducer).

Question 316: All of the following conditions show hyperthermia, EXCEPT:

A. Neuroleptic malignant syndrome
B. Phencyclidine use
C. Aspirin toxicity
D. None of the above (Correct Answer)

Explanation: ### Explanation The correct answer is **D (None of the above)** because all three conditions listed (Neuroleptic Malignant Syndrome, Phencyclidine use, and Aspirin toxicity) are well-recognized clinical causes of hyperthermia. **1. Neuroleptic Malignant Syndrome (NMS):** NMS is an idiosyncratic reaction to dopamine antagonists (e.g., Haloperidol). The pathophysiology involves central dopamine blockade in the hypothalamus, leading to a "reset" of the thermoregulatory set-point and severe muscle rigidity (lead-pipe rigidity). This combination results in life-threatening hyperthermia. **2. Phencyclidine (PCP) Use:** PCP is a dissociative anesthetic that causes psychomotor agitation, violent behavior, and seizures. Hyperthermia in PCP toxicity results from excessive muscular activity and increased metabolic rate. It is often associated with rhabdomyolysis. **3. Aspirin (Salicylate) Toxicity:** Salicylates act as **uncouplers of oxidative phosphorylation**. This process prevents the efficient production of ATP, causing the energy from the electron transport chain to be dissipated as heat instead of being stored as chemical energy. This leads to metabolic hyperpyrexia. --- ### High-Yield Clinical Pearls for NEET-PG: * **Malignant Hyperthermia:** Triggered by volatile anesthetics (Halothane) or Succinylcholine due to a mutation in the **RYR1 receptor**. Treatment of choice is **Dantrolene**. * **Serotonin Syndrome:** Often confused with NMS. Key differentiator: NMS has "lead-pipe" rigidity, while Serotonin Syndrome presents with **hyperreflexia and clonus**. * **Atropine Poisoning:** Causes hyperthermia ("Hot as a hare") due to the suppression of sweat gland activity (anhidrosis). * **Management Tip:** For severe hyperthermia (>106°F), physical cooling (ice water immersion) is prioritized over antipyretics like Paracetamol, which are ineffective in these toxidromes.

Question 317: What is the primary purpose of pharmacovigilance?

A. To monitor drug toxicity (Correct Answer)
B. To monitor unauthorized drug manufacture
C. Monitoring of students
D. Check costs

Explanation: **Explanation:** Pharmacovigilance (PV) is defined by the WHO as the science and activities relating to the **detection, assessment, understanding, and prevention of adverse effects** or any other drug-related problems. **Why Option A is Correct:** The primary goal of pharmacovigilance is to ensure patient safety by monitoring the safety profile of drugs after they have been released into the market (Phase IV clinical trials). Since pre-marketing trials (Phases I-III) involve a limited number of highly selected patients, rare or long-term toxicities often remain undetected until the drug is used by the general population. PV systems, such as spontaneous reporting, help identify these **Adverse Drug Reactions (ADRs)** and toxicities early. **Why Other Options are Incorrect:** * **Option B:** Monitoring unauthorized drug manufacture is the responsibility of **Drug Regulatory Authorities** (like CDSCO in India or the FDA) and law enforcement, not pharmacovigilance. * **Option C:** Monitoring students is an academic or administrative function and has no relation to clinical pharmacology. * **Option D:** Checking costs relates to **Pharmacoeconomics**, which evaluates the cost-benefit ratio of drug therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacovigilance Programme of India (PvPI):** Launched in 2010; the National Coordinating Centre is the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. * **Phase IV Trials:** Also known as Post-Marketing Surveillance; this is the core stage where pharmacovigilance occurs. * **Uppsala Monitoring Centre (UMC):** The WHO headquarters for international drug monitoring located in Sweden. * **Yellow Card Scheme:** A famous spontaneous reporting system for ADRs (originally from the UK).

Question 318: Tadalafil should NOT be used in which of the following conditions?

A. Diabetics
B. Patients on nitrates therapy (Correct Answer)
C. Pulmonary arterial hypertension
D. Erectile dysfunction

Explanation: **Explanation:** The correct answer is **Patients on nitrates therapy**. **Mechanism of Interaction:** Tadalafil is a selective **Phosphodiesterase-5 (PDE-5) inhibitor**. PDE-5 normally breaks down cyclic Guanosine Monophosphate (cGMP). By inhibiting this enzyme, Tadalafil increases cGMP levels, leading to smooth muscle relaxation and vasodilation. Nitrates (like Nitroglycerin or Isosorbide dinitrate) act as nitric oxide donors, which stimulate guanylate cyclase to produce more cGMP. When used together, they cause a **synergistic accumulation of cGMP**, leading to profound systemic vasodilation. This can result in **severe, life-threatening hypotension**, syncope, or myocardial infarction. Therefore, the co-administration of PDE-5 inhibitors and nitrates is an absolute contraindication. **Analysis of Incorrect Options:** * **A. Diabetics:** Erectile dysfunction is common in diabetics due to neuropathy and microvascular changes. Tadalafil is frequently prescribed and safe for these patients, provided they have no underlying unstable cardiac disease. * **C. Pulmonary Arterial Hypertension (PAH):** Tadalafil is FDA-approved for PAH (Group 1). It reduces pulmonary vascular resistance and improves exercise capacity. * **D. Erectile Dysfunction (ED):** This is the primary clinical indication for Tadalafil. Its long half-life (~17.5 hours) makes it unique ("the weekend pill"). **High-Yield Clinical Pearls for NEET-PG:** * **Time Gap:** If a patient has taken Tadalafil, nitrates should be avoided for at least **48 hours** (compared to 24 hours for Sildenafil). * **Other Indications:** Tadalafil is also used for the treatment of **Benign Prostatic Hyperplasia (BPH)**. * **Side Effects:** Common side effects include headache, dyspepsia, and back pain/myalgia. Unlike Sildenafil, it has less effect on PDE-6, so visual disturbances ("blue vision") are rare.

Question 319: Bone marrow aplasia is seen with all the following drugs except?

A. Methicillin (Correct Answer)
B. Chloramphenicol
C. Alpha methyl hydantoin
D. Phenylbutazone

Explanation: The question asks to identify the drug that does **not** typically cause bone marrow aplasia (aplastic anemia). **1. Why Methicillin is the Correct Answer:** Methicillin is a penicillinase-resistant penicillin. Its most characteristic and high-yield adverse effect is **interstitial nephritis** (a type of hypersensitivity reaction in the kidneys), not bone marrow suppression [1]. While most penicillins can rarely cause blood dyscrasias, methicillin is specifically associated with renal toxicity rather than aplastic anemia. **2. Analysis of Incorrect Options (Drugs that DO cause Aplastic Anemia):** * **Chloramphenicol:** This is the classic cause of idiosyncratic (irreversible) aplastic anemia [2]. It also causes dose-dependent (reversible) bone marrow suppression and "Gray Baby Syndrome" [2]. * **Alpha methyl hydantoin (Mephenytoin):** This is an anticonvulsant related to Phenytoin. Hydantoins are well-known for causing idiosyncratic blood dyscrasias, including aplastic anemia and agranulocytosis. * **Phenylbutazone:** An older NSAID that is now rarely used due to its high risk of severe bone marrow toxicity, specifically aplastic anemia and agranulocytosis. **Clinical Pearls for NEET-PG:** * **Gold Standard for Aplastic Anemia:** Chloramphenicol is the most frequently tested drug for this side effect. * **Other common culprits:** Gold salts, Penicillamine, Carbamazepine, and Cytotoxic drugs (Busulfan). * **Methicillin High-Yield Fact:** It is no longer used clinically due to its high incidence of interstitial nephritis; its primary role today is in the laboratory to define "MRSA" (Methicillin-Resistant *Staphylococcus aureus*) [1].

Question 320: Naltrexone is used to maintain abstinence following opioid withdrawal in addicts. It blocks which of the following features of opioid use, except?

A. Euphoriant effects of opioids
B. Craving for opioids (Correct Answer)
C. Miosis
D. Respiratory depression

Explanation: **Explanation:** **Naltrexone** is a long-acting, competitive **opioid receptor antagonist** with high affinity for $\mu$-receptors. Its primary mechanism is to occupy opioid receptors, thereby preventing exogenous opioids from binding and exerting their effects. **Why "Craving" is the correct answer:** Naltrexone is highly effective at blocking the pharmacological effects of opioids (like euphoria or respiratory depression) if a patient relapses. However, it **does not significantly reduce the psychological craving** for opioids. In fact, because it blocks the reward system, it may sometimes worsen the "drug hunger" in the early stages of treatment. This is a key clinical distinction from **Methadone** or **Buprenorphine** (agonists/partial agonists), which do satisfy and reduce cravings. **Analysis of Incorrect Options:** * **A. Euphoriant effects:** By blocking $\mu$-receptors in the reward pathway (nucleus accumbens), naltrexone prevents the "high" or euphoria associated with opioid use. * **C. Miosis:** Naltrexone reverses or blocks the pupillary constriction (pinpoint pupils) caused by opioid-induced stimulation of the Edinger-Westphal nucleus. * **D. Respiratory Depression:** As a competitive antagonist, it prevents opioids from depressing the brainstem respiratory centers, which is why related compounds (Naloxone) are used in acute overdose. **High-Yield Clinical Pearls for NEET-PG:** * **Naltrexone vs. Naloxone:** Naltrexone has high oral bioavailability and a long half-life (up to 10 hours), making it suitable for **maintenance of abstinence**. Naloxone has poor oral absorption and a short half-life, used for **acute overdose**. * **Alcoholism:** Naltrexone is also FDA-approved for **Alcohol Dependence** as it reduces the "reward" of drinking by blocking endogenous opioid pathways. * **Prerequisite:** Patients must be opioid-free for at least **7–10 days** before starting Naltrexone to avoid precipitating severe withdrawal.

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free